Pfizer Inc said on Monday it has started a mid-to-late-stage study testing its investigational oral antiviral drug for the prevention of Covid-19 infection among those who have been exposed to the virus.
The company and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG, have been racing to develop the first antiviral pill for Covid-19.
Pfizer said it would study the drug, PF-07321332, in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic Covid-19 infection.
The trial would test PF-07321332 with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.
Merck and partner Ridgeback Biotherapeutics said earlier this month they had begun enrolling patients in a late-stage trial of their experimental drug molnupiravir for prevention of Covid-19 infection.
Pfizer had also said earlier this month it started a mid-to-late-stage trial of PF-07321332 for the treatment of Covid-19 in non-hospitalized, symptomatic adult patients.
LEAVE A COMMENT Your email address will not be published. Required fields are marked*
Fugitive businessman close to Venezuela's Maduro extradited to US
Macron condemns ‘inexcusable’ Paris ?massacre of Algerians
America feels your pain, Biden says at memorial for law enforcement officers
Nasa launches first space probe to study Jupiter’s Trojan asteroids
Clinton recovering in hospital from infection
US ‘prepares to resume Trump-era asylum policy’
US to lift travel ban for fully jabbed from November 8
Former US president Bill Clinton in hospital
‘It was unbelievable’: Star Trek’s Shatner becomes real life astronaut